Upcoming event

Effect of sex on the oncological outcomes in response to immunotherapy and antibody-drug conjugates in patients with urothelial and kidney cancer: A systematic review and a network meta-analysis

European Urology Oncology, April 2024

Preparing for the worst: Management and predictive factors of open conversion during minimally invasive renal tumor surgery (UroCCR-135 study)

European Urology Open Science, May 2024

Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial

The LANCET oncology, March 2024

Real-world outcome of patients with advanced renal cell carcinoma and intermediate- or poor-risk international metastatic renal cell carcinoma database consortium criteria treated by immune-oncology combinations: Differential effectiveness by risk group?

European Urology Oncology, February 2024

Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS)

The Lancet Oncology, January 2024

Nephron Sparing Treatment (NEST) for small renal masses: A feasibility cohort-embedded randomised controlled trial comparing percutaneous cryoablation and robot-assisted partial nephrectomy

Development of a novel score (RENSAFE) to determine probability of acute kidney injury and renal functional decline post surgery: A multicenter analysis

Preoperative renal parenchyma volume as a predictor of kidney function following nephrectomy of complex renal masses

Patient-reported outcome measurement and reporting for patients with advanced renal cell carcinoma: A systematic literature review

Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

Risks and benefits of partial nephrectomy performed with limited or with zero ischaemia time

Next